The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.
Patients ≥ 19 years old
Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).
The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Patients with a mixture of other drug-eluting stents (DESs)
Terminal illness with life-expectancy ≤1 year.
Patients with cardiogenic shock
Jung-min Ahn
Lead sponsor
Asan Medical Center
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator